全文获取类型
收费全文 | 637篇 |
免费 | 59篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 2篇 |
基础医学 | 47篇 |
临床医学 | 120篇 |
内科学 | 262篇 |
皮肤病学 | 1篇 |
神经病学 | 109篇 |
特种医学 | 9篇 |
外科学 | 25篇 |
综合类 | 12篇 |
预防医学 | 45篇 |
眼科学 | 2篇 |
药学 | 34篇 |
中国医学 | 1篇 |
肿瘤学 | 25篇 |
出版年
2021年 | 4篇 |
2019年 | 5篇 |
2018年 | 6篇 |
2016年 | 5篇 |
2014年 | 5篇 |
2013年 | 6篇 |
2012年 | 14篇 |
2011年 | 16篇 |
2010年 | 13篇 |
2009年 | 7篇 |
2008年 | 20篇 |
2007年 | 15篇 |
2006年 | 20篇 |
2005年 | 26篇 |
2004年 | 28篇 |
2003年 | 29篇 |
2002年 | 30篇 |
2001年 | 24篇 |
2000年 | 30篇 |
1999年 | 22篇 |
1998年 | 9篇 |
1997年 | 7篇 |
1996年 | 11篇 |
1995年 | 9篇 |
1994年 | 7篇 |
1993年 | 11篇 |
1992年 | 24篇 |
1991年 | 25篇 |
1990年 | 26篇 |
1989年 | 22篇 |
1988年 | 23篇 |
1987年 | 21篇 |
1986年 | 27篇 |
1985年 | 18篇 |
1984年 | 16篇 |
1983年 | 7篇 |
1982年 | 7篇 |
1981年 | 6篇 |
1979年 | 7篇 |
1978年 | 12篇 |
1977年 | 6篇 |
1975年 | 5篇 |
1974年 | 10篇 |
1973年 | 9篇 |
1972年 | 5篇 |
1971年 | 5篇 |
1970年 | 5篇 |
1968年 | 3篇 |
1967年 | 5篇 |
1966年 | 3篇 |
排序方式: 共有696条查询结果,搜索用时 15 毫秒
1.
2.
3.
D E Vaughan P J Declerck E Van Houtte M De Mol D Collen 《Thrombosis and haemostasis》1992,68(1):60-63
The effects of human recombinant plasminogen activator inhibitor (rPAI-1) on thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) were studied in a rabbit model of jugular vein thrombosis. Two functionally distinct rPAI-1 preparations were used in these experiments, including latent rPAI-1 (approximately 2 units of t-PA neutralizing activity per micrograms protein) and reactivated rPAI-1 (approximately 150 units/micrograms). Simultaneous intravenous infusion over 4 h of 1.7 mg/kg of reactivated rPAI-1 (inhibitory capacity approximately 0.5 mg/kg rt-PA) with 0.5 mg/kg of rt-PA completely prevented lysis of a jugular venous thrombus, whereas an equivalent amount of latent PAI-1 did not significantly influence clot lysis. These findings demonstrate that reactivated human rPAI-1 efficiently neutralizes thrombolysis with rt-PA in vivo. Since previous studies have suggested that elevated endogenous levels of PAI-1 do not attenuate the thrombolytic potency of rt-PA in the endotoxin-treated model, we compared the stability of complexes formed by 125I-rt-PA with reactivated human rPAI-1 and with rabbit PAI-1 in vitro. Our findings indicate that both forms of PAI-1 form SDS-stable complexes following incubation with 125I-rt-PA. Thus, it seems likely that elevated levels of active PAI-1 can negate the thrombolytic effects of rt-PA in vivo and argues against the possibility that t-PA can dissociate from PAI-1 and have its activity restored in the presence of a thrombus.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
4.
Georgios Amoiridis Ludwig Gutmann Dennis E. Wilkins Raja Sawaya Alain Lagueny Roger Marthan Philippe Schuermans Philippe Le Collen Xavier Ferrer Jean Julien Reha Kuruoglu Shin J. Oh Brian Thompson A. Aggarwal L. Gutmann A. Gutierrez Okifumi Nakazato Russel Johnsen Philip Morling B. A. Kakulas 《Muscle & nerve》1994,17(2):245-253
5.
6.
J Philippé F Offner P J Declerck G Leroux-Roels D Vogelaers G Baele D Collen 《Thrombosis and haemostasis》1991,65(3):291-295
Sepsis is often associated with hemostatic dysfunction. This study aimed to relate changes in fibrinolysis and coagulation parameters to sepsis and sepsis outcome. Urokinase-type plasminogen activator (u-PA) antigen, tissue-type plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor (PAI) type 1 antigen, PAI activity, antithrombin (AT) III activity, and protein C activity were measured in 24 patients suffering from sepsis or septic shock and the results were compared with those observed in 30 non-sepsis patients with severe infectious disease. The u-PA level was markedly increased in plasma of sepsis patients as compared to non-sepsis patients (11.5 +/- 9.4 versus 1.6 +/- 1.5 ng/ml, p less than 0.0001). PAI-1 antigen and t-PA activity showed a significant increase in sepsis patients (320 +/- 390 ng/ml versus 120 +/- 200 ng/ml, and 3.0 +/- 3.6 IU/ml versus 1.0 +/- 0.7 IU/ml, respectively, p less than 0.01). AT III was decreased in sepsis patients (58 +/- 28% in sepsis versus 79 +/- 26% in severe infectious disease, p less than 0.01) as was protein C (30 +/- 18% versus 58 +/- 27%, p less than 0.001). No significant difference was found for t-PA antigen nor for PAI activity. Nonsurvivors of sepsis were distinguished mainly by a high u-PA antigen level and increased t-PA activity. It is concluded that plasma u-PA antigen showed the strongest significant difference, among the parameters evaluated, between sepsis and severe infection. u-PA antigen may be of prognostic value in patients admitted to the medical intensive care unit for severe infectious disease. 相似文献
7.
D Collen L Nelles F De Cock G Lemmens T Van Coetsem E Demarsin H R Lijnen 《Thrombosis research》1992,65(3):421-438
K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency in animal models of venous and arterial thrombosis, which consists of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA), was produced and conditioned for use in patients. Chinese hamster ovary cells were transfected with an expression plasmid containing the K1K2Pu cDNA, high producer cell lines were selected and scaled up in 800 cm2 roller bottles, and 350 ml conditioned cell culture medium was harvested 3 to 7 times at 2 to 5 day intervals. Batches of 21 +/- 4 liter (mean +/- SD, n = 28) containing 1.8 +/- 0.6 mg/l of K1K2Pu related antigen were purified by chromatography on Copper chelate-Sepharose and immunoadsorption on an insolubilized murine monoclonal antibody (MA-1C8). Yields were 8.6 +/- 3.4 mg K1K2Pu per batch with a specific activity of 83,000 +/- 44,000 IU/mg. The final material, obtained at a concentration of approximately 0.7 mg/ml, was dialyzed against 0.3 M NaCl, 0.02 M Tris-HCl buffer, pH 7.5, containing 0.01% Tween 80 and 10 KIU/ml aprotinin. It was homogeneous on SDS-PAGE, contained 6.5 +/- 6.9 percent two chain material and the contamination with murine monoclonal antibody was less than 0.1 percent. After filtration of pools of 3 to 5 selected batches on 0.22 microns Millipore filters the material was sterile and virus free by routine screening; it was obtained at a concentration of approximately 0.5 mg/ml with a specific activity of 110,000 +/- 16,000 IU/mg (mean +/- SD, n = 3) and an endotoxin content of 0.5 to 7 units/mg. Bolus injection at a dose of 1 mg/kg in mice did not produce weight loss within 8 days. Thus, this material appears to be suitable for the investigation on a pilot scale of the pharmacokinetic and thrombolytic properties of K1K2Pu in patients with thromboembolic disease. 相似文献
8.
9.
Strategies for the improvement of thrombolytic agents 总被引:14,自引:0,他引:14
10.
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS 总被引:18,自引:0,他引:18
Storkebaum E Lambrechts D Dewerchin M Moreno-Murciano MP Appelmans S Oh H Van Damme P Rutten B Man WY De Mol M Wyns S Manka D Vermeulen K Van Den Bosch L Mertens N Schmitz C Robberecht W Conway EM Collen D Moons L Carmeliet P 《Nature neuroscience》2005,8(1):85-92
Neurotrophin treatment has so far failed to prolong the survival of individuals affected with amyotrophic lateral sclerosis (ALS), an incurable motoneuron degenerative disorder. Here we show that intracerebroventricular (i.c.v.) delivery of recombinant vascular endothelial growth factor (Vegf) in a SOD1(G93A) rat model of ALS delays onset of paralysis by 17 d, improves motor performance and prolongs survival by 22 d, representing the largest effects in animal models of ALS achieved by protein delivery. By protecting cervical motoneurons, i.c.v. delivery of Vegf is particularly effective in rats with the most severe form of ALS with forelimb onset. Vegf has direct neuroprotective effects on motoneurons in vivo, because neuronal expression of a transgene expressing the Vegf receptor prolongs the survival of SOD1(G93A) mice. On i.c.v. delivery, Vegf is anterogradely transported and preserves neuromuscular junctions in SOD1(G93A) rats. Our findings in preclinical rodent models of ALS may have implications for treatment of neurodegenerative disease in general. 相似文献